
FDA Approves Ustekinumab-Stba, Biosimilar to Stelara, for Pediatric Patients With PsO or PsA
The FDA approved ustekinumab-stba (Steqeyma; Celltrion), a biosimilar to Stelara (ustekinumab; Janssen Pharmaceuticals), for the treatment of plaque psoriasis (PsO) or psoriatic arthritis (PsA) in pediatric patients aged 6 to 17 years who weigh less than …